Association between miRNA polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-10-21 DOI:10.1080/17520363.2025.2577626

Young Ho Lee, Gwan Gyu Song

{"title":"Association between miRNA polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis.","authors":"Young Ho Lee, Gwan Gyu Song","doi":"10.1080/17520363.2025.2577626","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the association between microRNA (miRNA) polymorphisms and rheumatoid arthritis (RA) susceptibility through meta-analysis.Methods: We systematically searched MEDLINE, EMBASE, and Web of Science for case-control studies examining five miRNA polymorphisms: miR-146a rs2910164, miR-499 rs3746444, miR-196a2 rs11614913, miR-155 rs767649, and miR-149 rs2292832. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-effects models.Results: Twenty-three studies comprising 4,303 RA patients and 5,337 controls were included. Significant associations were identified for three polymorphisms. MiR-499 rs3746444 demonstrated increased RA risk across multiple genetic models (allelic, recessive, and homozygote). MiR-146a rs2910164 showed population-specific effects, conferring protection in Arabs (OR = 0.666, 95% CI = 0.520-0.853, p = 0.001) but not in Asian or European populations. The miR-149 rs2292832 A allele exhibited strong protective effects (OR = 0.314, 95% CI = 0.215-0.458, p < 0.001). No significant associations were observed for miR-196a2 rs11614913 or miR-155 rs767649 polymorphisms.Conclusions: This meta-analysis demonstrates that miRNA polymorphisms exhibit variable associations with RA susceptibility. MiR-499 rs3746444 increases risk, while miR-146a rs2910164 and miR-149 rs2292832 provide protection, with ethnic-specific effects for miR-146a rs2910164.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-9"},"PeriodicalIF":2.1000,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2577626","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the association between microRNA (miRNA) polymorphisms and rheumatoid arthritis (RA) susceptibility through meta-analysis.

Methods: We systematically searched MEDLINE, EMBASE, and Web of Science for case-control studies examining five miRNA polymorphisms: miR-146a rs2910164, miR-499 rs3746444, miR-196a2 rs11614913, miR-155 rs767649, and miR-149 rs2292832. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-effects models.

Results: Twenty-three studies comprising 4,303 RA patients and 5,337 controls were included. Significant associations were identified for three polymorphisms. MiR-499 rs3746444 demonstrated increased RA risk across multiple genetic models (allelic, recessive, and homozygote). MiR-146a rs2910164 showed population-specific effects, conferring protection in Arabs (OR = 0.666, 95% CI = 0.520-0.853, p = 0.001) but not in Asian or European populations. The miR-149 rs2292832 A allele exhibited strong protective effects (OR = 0.314, 95% CI = 0.215-0.458, p < 0.001). No significant associations were observed for miR-196a2 rs11614913 or miR-155 rs767649 polymorphisms.

Conclusions: This meta-analysis demonstrates that miRNA polymorphisms exhibit variable associations with RA susceptibility. MiR-499 rs3746444 increases risk, while miR-146a rs2910164 and miR-149 rs2292832 provide protection, with ethnic-specific effects for miR-146a rs2910164.

查看原文本刊更多论文

miRNA多态性与类风湿关节炎易感性之间的关联：一项荟萃分析。

目的：通过荟萃分析，探讨microRNA （miRNA）多态性与类风湿关节炎（RA）易感性的关系。方法：我们系统地检索了MEDLINE、EMBASE和Web of Science的病例对照研究，检查了五种miRNA多态性：miR-146a rs2910164、miR-499 rs3746444、miR-196a2 rs11614913、miR-155 rs767649和miR-149 rs2292832。使用随机效应模型计算95%置信区间（ci）的优势比（ORs）。结果：纳入了23项研究，包括4303名RA患者和5337名对照。在三个多态性中发现了显著的关联。MiR-499 rs3746444在多种遗传模型（等位基因、隐性和纯合子）中显示RA风险增加。MiR-146a rs2910164显示出人群特异性效应，在阿拉伯人中具有保护作用（OR = 0.666, 95% CI = 0.520-0.853, p = 0.001），但在亚洲或欧洲人群中没有。miR-149 rs2292832a等位基因表现出较强的保护作用（OR = 0.314, 95% CI = 0.215-0.458, p）。结论：该荟萃分析表明，miRNA多态性与RA易感性表现出可变的相关性。MiR-499 rs3746444增加风险，而miR-146a rs2910164和miR-149 rs2292832提供保护，miR-146a rs2910164具有种族特异性作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.